Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
iBio to Participate in Upcoming Healthcare Investor Conferences
04:01pm, Tuesday, 02'nd Jun 2026
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary d
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
07:00am, Tuesday, 02'nd Jun 2026
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th May 2026
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with pr
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
02:03am, Friday, 10'th Apr 2026
iBio (NASDAQ: IBIO) is seeking to narrow what it views as a growing "trust gap" between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
07:00am, Wednesday, 08'th Apr 2026
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
01:46am, Monday, 02'nd Mar 2026
iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies bas
iBio to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
01:26am, Tuesday, 24'th Feb 2026
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 10'th Feb 2026
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:00am, Monday, 02'nd Feb 2026
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
02:24am, Sunday, 18'th Jan 2026
Vincerx Pharma (NASDAQ: VINC - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses b
iBio (NYSEMKT:IBIO) Trading 8.3% Higher – Here’s Why
02:27am, Saturday, 10'th Jan 2026
Shares of iBio, Inc. (NYSEMKT:IBIO - Get Free Report) traded up 8.3% during trading on Friday. The stock traded as high as $2.35 and last traded at $2.35. 1,928,910 shares were traded during trading,
